MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Daniel P. Petrylak et al.|Nature|2014Cited by 2.4k
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271
Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin SensitivityJorge Gómez‐Miragaya, Eva González‐Suárez, Ander Díaz‐Navarro et al.|Cancer Research|2019Cited by 19